Physician profile
Vanessa Lima
NPI 1962522672
$2,048.24
in general payments reported to CMS, 2019-2025
21 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $132 · 2021: $231 · 2022: $278 · 2023: $215 · 2024: $615 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $284.97 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $243.65 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Allergan, INC. | $187.66 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $162.55 | 2019-2025 | Cequa |
| Abbvie INC. | $148.94 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $139.27 | 2021-2025 | Acthar |
| Alcon Vision LLC | $124.03 | 2022-2025 | Tryptyr, Rocklatan, Argos |
| Amgen INC. | $113.75 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $98.69 | 2021-2023 | Tepezza |
| Oyster Point Pharma, INC. | $88.83 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $75.21 | 2019-2023 | |
| Harrow Eye, LLC | $72.67 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.06 | 2019-2021 | |
| Dompe US, INC. | $51.13 | 2019-2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $47.06 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $40.67 | 2022 | |
| Apellis Pharmaceuticals, INC. | $26.58 | 2025 | Syfovre |
| Glaxosmithkline, LLC. | $23.85 | 2025 | Blenrep |
| Johnson & Johnson Surgical Vision, INC. | $18.65 | 2019 | |
| Shire North American Group INC | $16.69 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Lima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.